A number of individual top biomarkers are known to be modulated by medications in current clinical use for treating depression, such as by lithium (NRG1, PRPS1, CD47), antidepressants (SLC6A4, DOCK10, NRG1, CD47) and the nutraceutical omega-3 fatty acids (GLO1, SLC6A4, CD47, GLS, HNRNPDL) (Fig. S4 and Table 3 and S4). This evidence concerns the gene GLS and depressive symptom measurement.